Probiotics

Is Lactobacillus rhamnosus the same as LGG?

Lactobacillus rhamnosus is a species and LGG is one strain within it, so research on LGG applies to that strain and not to every L. rhamnosus product.

By Audrey Jung and Yuzu Tay

Updated 22 Nov 2026 · 11 min read

Share
Is Lactobacillus rhamnosus the same as LGG?

Key takeaways

  • Lactobacillus rhamnosus is a species, and LGG is one strain within it, now named Lacticaseibacillus rhamnosus GG.
  • Strains of one species differ in some of their genes, so a trait or trial result for LGG does not carry over to other L. rhamnosus strains.
  • LGG has been studied most in children with diarrhoea, and the results differ from trial to trial.
  • Ask a doctor or pharmacist before starting a probiotic, especially if you take medication or are giving it to a child.

Lactobacillus rhamnosus GG, usually shortened to LGG, is one of the most widely used probiotic strains and one of the most studied.[1, 2] Because the full name starts with Lactobacillus rhamnosus, it is easy to assume that any probiotic with that species on the label is LGG, or that it works the same way.

They might not the same thing. Lactobacillus rhamnosus is a species of bacteria, and LGG (Lactobacillus rhamnosus GG) is one strain within it.[1, 3] The difference matters when you choose a probiotic, because strains of the same species can differ in their genes and in how they behave in the gut.[4] Results from trials of LGG belong to that strain, not to every product that contains L. rhamnosus.

This article explains how a species differs from a strain, where LGG comes from, what the research on it does and does not show, how it compares with related strains, who should be careful with it and what to consider if you take it as a supplement.

Species and strains explained

Every bacterium has a name with up to three parts, a bit like an address. The first word is the genus, a broad group of related bacteria, like a city. The second word is the species, a narrower group within it, like a street. The code that sometimes follows is the strain, one specific type within that species, like a house number.

In Lacticaseibacillus rhamnosus GG, Lacticaseibacillus is the genus, rhamnosus is the species and GG is the strain. You may also see it called Lactobacillus rhamnosus GG, its name before this group of bacteria was renamed in 2020.[3]

Strains of the same species are closely related but not identical. When researchers compared 100 L. rhamnosus strains with LGG, each one carried between about 87% and 100% of LGG's genes.[4] Those differences can change how a strain behaves in the gut, so research on LGG tells you about LGG, not about every L. rhamnosus strain.

Where LGG comes from and what sets it apart

LGG was first found in a stool sample from a healthy adult by Sherwood Gorbach and Barry Goldin, and the letters GG come from their surnames.[1] In 1989 it became the first Lactobacillus strain to be patented, because it can survive stomach acid and bile and stick to the cells lining the gut.[2]

LGG has tiny hair-like structures on its surface, called pili, that help it stick to the mucus lining the gut.[5] Not every L. rhamnosus strain has them. LC705, a closely related strain used in dairy products, lacks the genes for these pili and sticks to mucus poorly.[5] Across 100 L. rhamnosus strains, about 40% of those found in people made working pili, compared with 13% of those found in dairy products.[4]

How long LGG stays in your gut

LGG survives the trip through the stomach and small intestine well enough to reach the gut alive. In a study of 76 volunteers, LGG was found in the stool of everyone who took it in fermented milk or whey, and of 86% of those who took it as a frozen concentrate.[6]

Once there, LGG can hold on to the gut lining, but only for a while. Its pili let it stick to the layer of mucus that coats the inside of the gut, where it can interact with your resident bacteria and the cells of your gut wall.[1]

That hold is temporary. Once people stopped taking LGG, it was still found in the stool of 87% of volunteers four days later, but in only 33% after seven days.[6] Samples taken from the gut lining suggest it can stay there a little longer than stool tests show[1], but it does not settle in for good.

The reason is competition. The bacteria already living in your gut, together with the gut lining, limit which new strains can settle, which researchers call colonisation resistance. In a study that sampled the gut lining directly while people took an 11-strain probiotic mix, how well the strains settled differed from person to person.[7] So sticking to the gut and staying in it are different things. LGG does the first while you take it, but not the second.

Lactobacillus rhamnosus GG benefits and what the research shows

LGG has about three decades of research behind it.[2] Its clearest evidence is for diarrhoea in children, especially diarrhoea linked to antibiotics. Trials in other areas, such as abdominal pain, infections, eczema and mood, are fewer or smaller, and some careful trials found no effect.

Diarrhoea during a course of antibiotics

Some people develop loose stools during or soon after a course of antibiotics, which doctors call antibiotic-associated diarrhoea. A systematic review of 12 randomised trials found that, across 11 trials with 1,308 children and adults, LGG lowered the risk of this kind of diarrhoea from about 22% to 12%.[8] When children and adults were looked at separately, the difference was significant only in children. In adults it was not significant overall, except in people taking antibiotics to clear the stomach bacterium Helicobacter pylori.

A working group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) later recommended that children taking antibiotics who are given a probiotic receive LGG or the yeast Saccharomyces boulardii, to lower the risk of antibiotic-associated diarrhoea.[9]

Stomach bugs in young children

Acute gastroenteritis, a sudden gut infection that causes diarrhoea and often vomiting, is one of the uses LGG has been tested for most, and the results are mixed. A 2013 review pooled 11 trials with 2,444 children and found that LGG shortened diarrhoea by about one day compared with placebo or no treatment. The effect was clearer in trials run in Europe than in trials elsewhere.[10]

Single trials show the same spread. In an open-label trial of 200 young children in north India, diarrhoea lasted about 60 hours with LGG and 78 hours without it, though the trial had no placebo group.[11] In a large placebo-controlled trial of 971 children aged three months to four years, seen at 10 emergency departments in the US, LGG made no significant difference.[12] These two trials differ in more than their results. They took place in different countries, used different doses and only one compared LGG with a placebo, so the gap cannot be put down to LGG alone.

Abdominal pain in children

In an eight-week randomised, placebo-controlled trial of 141 children in Italy with irritable bowel syndrome or functional abdominal pain (recurring tummy pain with no clear medical cause), LGG reduced how often and how badly pain occurred. The effect was mainly in the children with irritable bowel syndrome, and it was still seen after eight weeks of follow-up once they had stopped taking LGG. In that group, LGG also lowered intestinal permeability, a measure of how easily substances pass through the gut lining.[13]

Infections picked up in hospital

In a placebo-controlled trial of 742 children staying in hospital in Croatia, a fermented milk drink containing LGG lowered the risk of gut and respiratory infections picked up on the ward.[14]

Eczema in babies at high risk of allergy

In a placebo-controlled trial in Finland, pregnant women from families with a history of eczema, hay fever or asthma took LGG for two to four weeks before giving birth, and their babies took it for six months after. By age two, eczema had developed in 23% of the children given LGG, compared with 46% of those given placebo.[15] A later trial with a similar design found no effect on eczema[16], so the evidence for this use is mixed.

Mood and inflammation in adults with heart disease

In a randomised, placebo-controlled trial of 96 adults with coronary artery disease in Iran, LGG taken with the prebiotic inulin for eight weeks lowered depression and anxiety scores and the inflammation markers hs-CRP and TNF-α.[17] This is a single trial in people with a specific condition, and the effect came from LGG and inulin together, so it does not show what LGG does for mood on its own.

Research on other Lacticaseibacillus strains

Evidence for LGG does not carry over to other L. rhamnosus strains by default, because strains of one species differ in their genes, as described above. Each strain needs its own trials.

Other strains in the same genus have their own trials, and their results belong to them in the same way. Lacticaseibacillus also includes the species L. paracasei and L. casei, which sat in the old genus Lactobacillus before the 2020 renaming.[3]

  • L. rhamnosus HN001 and eczema. In a placebo-controlled trial in New Zealand, pregnant women took HN001 from 35 weeks of pregnancy and their babies took it until age two. HN001 roughly halved how many children developed eczema by age two, while a Bifidobacterium strain tested in the same trial had no significant effect.[18]
  • L. rhamnosus HN001 and mood after birth. In a separate placebo-controlled trial of 423 pregnant women in New Zealand, those given HN001 reported lower depression and anxiety scores after their babies were born.[19]
  • L. paracasei Shirota and constipation. This strain was formerly called Lactobacillus casei Shirota. In a four-week placebo-controlled trial of 70 adults with chronic constipation in Germany, a probiotic drink containing it improved self-reported constipation and stool consistency, but not bloating or wind.[20]
  • L. paracasei CNCM I-1518 and infections in older adults. This strain was formerly called Lactobacillus casei DN-114 001. In a controlled trial of 1,072 adults aged 70 and over in France, a fermented dairy drink containing it did not reduce the number of common infections, but the infections that did occur were shorter, especially colds and other upper respiratory infections.[21]

Safety and who should take care

LGG has been studied since it was patented in 1989.[2] The main safety concern is for people who are seriously ill. At a children's hospital in the US, 6 of 522 patients in intensive care who were given LGG developed a bloodstream infection with the probiotic strain itself, confirmed by genome sequencing, compared with almost none of the more than 21,000 patients who were not given it.[22]

Premature babies are another group to be careful with. The US Food and Drug Administration has warned that premature babies given probiotics in hospital are at risk of serious, potentially fatal infections from the bacteria or fungi in those products. The warning covers probiotics in general rather than LGG specifically.[23] If you are seriously ill, are in hospital or are caring for a premature baby, speak to a doctor before using any probiotic.

Taking LGG as a supplement

The amount matters. Trials used set amounts, from about 2 billion to 20 billion CFU a day[12, 17], and their results apply to those amounts.

Taking it regularly matters. LGG fades from most people's gut within about a week of stopping, so it stays present only while you keep taking it.[6]

Product quality matters. A review by ESPGHAN's working group on probiotics found problems with commercial probiotic products, including which microorganisms they contained, how many there were and contamination with other microorganisms. It also noted that manufacturing can affect how many bacteria stay alive.[24]

Other strains in the same product matter. Most of the LGG trials in this article tested LGG on its own, and one tested it with the prebiotic inulin, so they do not show how LGG works alongside other strains in a multi-strain product.

Different people look for probiotics for different reasons, such as digestion, mood, energy or general upkeep. A targeted approach starts with your need and then looks at which formulations have been tailored for it.

Three AMILI Daily Synbiotics contain LGG. Complete and Digestion Daily Synbiotics pair it with L. plantarum at 7 billion CFU each, with Digestion also adding L. reuteri, and Mind & Brain Daily Synbiotics combines it with L. paracasei and L. plantarum at 6 billion CFU each. Each capsule pairs selected probiotic strains with prebiotics and postbiotics, and every formula is built on AMILI's gut microbiome library of about 25,000 gut samples from people living in Asia. If you take medication or belong to a vulnerable group, ask your doctor or pharmacist before you start.

Glossary

  • Acute gastroenteritis: a sudden gut infection that causes diarrhoea and often vomiting.
  • Antibiotic-associated diarrhoea: loose stools that develop during or after a course of antibiotics.
  • CFU (colony-forming units): a count of live bacteria able to multiply.
  • Colonisation resistance: the way the bacteria already in your gut, together with the gut lining, limit which new strains can settle.
  • Eczema: an itchy, inflamed skin condition that often starts in early childhood.
  • ESPGHAN: the European Society for Paediatric Gastroenterology, Hepatology and Nutrition.
  • Genus: a broad group of related bacteria, such as Lacticaseibacillus.
  • Open-label trial: a trial in which participants and researchers know who receives the treatment (unblinded).
  • Pili: hair-like structures on a bacterial surface.
  • Placebo-controlled trial: a trial that compares a treatment with a look-alike product that has no active ingredient.
  • Probiotic: live microorganisms that give a health benefit when given in adequate amounts.[25]
  • Randomised controlled trial: a trial that assigns participants to groups by chance.
  • Species: a group of related strains within a genus, such as Lacticaseibacillus rhamnosus.
  • Strain: one specific type within a species, identified by a code such as GG.
  • Systematic review: a study that gathers and assesses all the trials on a question, and may pool their results.

Frequently asked questions

No. Lactobacillus rhamnosus is the species, and LGG is one strain within it.[1]

References

  1. 1.Segers, Marijke E., and Sarah Lebeer. "Towards a Better Understanding of Lactobacillus rhamnosus GG-Host Interactions." Microbial Cell Factories, vol. 13, suppl. 1, 2014, article S7, https://doi.org/10.1186/1475-2859-13-S1-S7.
  2. 2.Capurso, Lucio. "Thirty Years of Lactobacillus rhamnosus GG: A Review." Journal of Clinical Gastroenterology, vol. 53, suppl. 1, 2019, pp. S1-S41, https://doi.org/10.1097/MCG.0000000000001170.
  3. 3.Zheng, Jinshui, et al. "A Taxonomic Note on the Genus Lactobacillus: Description of 23 Novel Genera, Emended Description of the Genus Lactobacillus Beijerinck 1901, and Union of Lactobacillaceae and Leuconostocaceae." International Journal of Systematic and Evolutionary Microbiology, vol. 70, no. 4, 2020, pp. 2782-858, https://doi.org/10.1099/ijsem.0.004107.
  4. 4.Douillard, François P., et al. "Comparative Genomic and Functional Analysis of 100 Lactobacillus rhamnosus Strains and Their Comparison with Strain GG." PLoS Genetics, vol. 9, no. 8, 2013, article e1003683, https://doi.org/10.1371/journal.pgen.1003683.
  5. 5.Kankainen, Matti, et al. "Comparative Genomic Analysis of Lactobacillus rhamnosus GG Reveals Pili Containing a Human-Mucus Binding Protein." Proceedings of the National Academy of Sciences, vol. 106, no. 40, 2009, pp. 17193-98, https://doi.org/10.1073/pnas.0908876106.
  6. 6.Goldin, Barry R., et al. "Survival of Lactobacillus Species (Strain GG) in Human Gastrointestinal Tract." Digestive Diseases and Sciences, vol. 37, no. 1, 1992, pp. 121-28, https://doi.org/10.1007/BF01308354.
  7. 7.Zmora, Niv, et al. "Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features." Cell, vol. 174, no. 6, 2018, pp. 1388-1405.e21, https://doi.org/10.1016/j.cell.2018.08.041.
  8. 8.Szajewska, Hania, and Maciej Kołodziej. "Systematic Review with Meta-Analysis: Lactobacillus rhamnosus GG in the Prevention of Antibiotic-Associated Diarrhoea in Children and Adults." Alimentary Pharmacology & Therapeutics, vol. 42, no. 10, 2015, pp. 1149-57, https://doi.org/10.1111/apt.13404.
  9. 9.Szajewska, Hania, et al. "Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children." Journal of Pediatric Gastroenterology and Nutrition, vol. 62, no. 3, 2016, pp. 495-506, https://doi.org/10.1097/MPG.0000000000001081.
  10. 10.Szajewska, Hania, et al. "Meta-Analysis: Lactobacillus GG for Treating Acute Gastroenteritis in Children – Updated Analysis of Randomised Controlled Trials." Alimentary Pharmacology & Therapeutics, vol. 38, no. 5, 2013, pp. 467-76, https://doi.org/10.1111/apt.12403.
  11. 11.Aggarwal, Sunny, et al. "Lactobacillus GG for Treatment of Acute Childhood Diarrhoea: An Open Labelled, Randomized Controlled Trial." Indian Journal of Medical Research, vol. 139, no. 3, 2014, pp. 379-85, ijmr.org.in/lactobacillus-gg-for-treatment-of-acute-childhood-diarrhoea-an-open-labelled-randomized-controlled-trial.
  12. 12.Schnadower, David, et al. "Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children." New England Journal of Medicine, vol. 379, no. 21, 2018, pp. 2002-14, https://doi.org/10.1056/NEJMoa1802598.
  13. 13.Francavilla, Ruggiero, et al. "A Randomized Controlled Trial of Lactobacillus GG in Children with Functional Abdominal Pain." Pediatrics, vol. 126, no. 6, 2010, pp. e1445-52, https://doi.org/10.1542/peds.2010-0467.
  14. 14.Hojsak, Iva, et al. "Lactobacillus GG in the Prevention of Nosocomial Gastrointestinal and Respiratory Tract Infections." Pediatrics, vol. 125, no. 5, 2010, pp. e1171-77, https://doi.org/10.1542/peds.2009-2568.
  15. 15.Kalliomäki, Marko, et al. "Probiotics in Primary Prevention of Atopic Disease: A Randomised Placebo-Controlled Trial." The Lancet, vol. 357, no. 9262, 2001, pp. 1076-79, https://doi.org/10.1016/S0140-6736(00)04259-8.
  16. 16.Kopp, Matthias V., et al. "Randomized, Double-Blind, Placebo-Controlled Trial of Probiotics for Primary Prevention: No Clinical Effects of Lactobacillus GG Supplementation." Pediatrics, vol. 121, no. 4, 2008, pp. e850-56, https://doi.org/10.1542/peds.2007-1492.
  17. 17.Moludi, Jalal, et al. "The Effects of Co-Administration of Probiotics and Prebiotics on Chronic Inflammation, and Depression Symptoms in Patients with Coronary Artery Diseases: A Randomized Clinical Trial." Nutritional Neuroscience, vol. 25, no. 8, 2022, pp. 1659-68, https://doi.org/10.1080/1028415X.2021.1889451.
  18. 18.Wickens, Kristin, et al. "A Differential Effect of 2 Probiotics in the Prevention of Eczema and Atopy: A Double-Blind, Randomized, Placebo-Controlled Trial." Journal of Allergy and Clinical Immunology, vol. 122, no. 4, 2008, pp. 788-94, https://doi.org/10.1016/j.jaci.2008.07.011.
  19. 19.Slykerman, Rebecca F., et al. "Effect of Lactobacillus rhamnosus HN001 in Pregnancy on Postpartum Symptoms of Depression and Anxiety: A Randomised Double-Blind Placebo-Controlled Trial." EBioMedicine, vol. 24, 2017, pp. 159-65, https://doi.org/10.1016/j.ebiom.2017.09.013.
  20. 20.Koebnick, Corinna, et al. "Probiotic Beverage Containing Lactobacillus casei Shirota Improves Gastrointestinal Symptoms in Patients with Chronic Constipation." Canadian Journal of Gastroenterology, vol. 17, no. 11, 2003, pp. 655-59, https://doi.org/10.1155/2003/654907.
  21. 21.Guillemard, Eric, et al. "Consumption of a Fermented Dairy Product Containing the Probiotic Lactobacillus casei DN-114001 Reduces the Duration of Respiratory Infections in the Elderly in a Randomised Controlled Trial." British Journal of Nutrition, vol. 103, no. 1, 2010, pp. 58-68, https://doi.org/10.1017/S0007114509991395.
  22. 22.Yelin, Idan, et al. "Genomic and Epidemiological Evidence of Bacterial Transmission from Probiotic Capsule to Blood in ICU Patients." Nature Medicine, vol. 25, no. 11, 2019, pp. 1728-32, https://doi.org/10.1038/s41591-019-0626-9.
  23. 23.US Food and Drug Administration. "Warning Regarding Use of Probiotics in Preterm Infants." 29 Sept. 2023, www.fda.gov/media/172606/download.
  24. 24.Kolaček, Sanja, et al. "Commercial Probiotic Products: A Call for Improved Quality Control. A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics." Journal of Pediatric Gastroenterology and Nutrition, vol. 65, no. 1, 2017, pp. 117-24, https://doi.org/10.1097/MPG.0000000000001603.
  25. 25.Hill, Colin, et al. "Expert Consensus Document: The International Scientific Association for Probiotics and Prebiotics Consensus Statement on the Scope and Appropriate Use of the Term Probiotic." Nature Reviews Gastroenterology & Hepatology, vol. 11, no. 8, 2014, pp. 506-14, https://doi.org/10.1038/nrgastro.2014.66.
  26. 26.Szajewska, Hania, et al. "Probiotics for the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications." Journal of Pediatric Gastroenterology and Nutrition, vol. 76, no. 2, 2023, pp. 232-47, https://doi.org/10.1097/MPG.0000000000003633.

This article is for general information and does not replace advice from your doctor. Speak to a healthcare professional before making changes to your treatment.

Written

Written by

Audrey Jung

Written by

Yuzu Tay

Yuzu Tay is a science communicator trained in biomedical engineering. Her focus is on translating and sharing real science to help people make better decisions about their health.

View profile
Smiling woman in a cream top beside a bunch of flowers

Start with your gut

Get a clear picture of your microbiome and a plan built around it.